Page last updated: 2024-11-05

dicloxacillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18381
CHEMBL ID893
CHEBI ID4511
SCHEMBL ID23955
MeSH IDM0006293

Synonyms (98)

Synonym
BRD-K05673000-323-02-8
DIVK1C_000658
KBIO1_000658
(2s,5r,6r)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SPECTRUM_000932
SPECTRUM5_000869
BSPBIO_002171
IDI1_000658
PRESTWICK2_000450
BSPBIO_000500
BPBIO1_000550
3116-76-5
C06950
dicloxacillin
(2s,5r,6r)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DB00485
D02348
dicloxacillin (usan/inn)
brl-1702
dynapen
dicloxacilline [inn-french]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta))-
6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
dicloxaciclin
3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolylpenicillin
dichloroxacillin
hsdb 3222
diclossacillina [dcit]
6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
dicloxacilin
brl 1702
dicloxacilina [inn-spanish]
dicloxacillinum [inn-latin]
methyldichlorophenylisoxazolylpenicillin
einecs 221-488-3
r-13423
dicloxacillin [usan:inn:ban]
dicloxacycline
KBIO3_001391
KBIOGR_001053
KBIOSS_001412
KBIO2_003980
KBIO2_001412
KBIO2_006548
NINDS_000658
SPBIO_002439
SPECTRUM4_000507
SPECTRUM2_000981
SPBIO_001041
PRESTWICK1_000450
PRESTWICK0_000450
SPECTRUM3_000386
PRESTWICK3_000450
dicloxacillinum
CHEBI:4511 ,
6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid
dicloxacilina
dicloxacilline
CHEMBL893
(2s,5r,6r)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
unii-cof19h7wbk
cof19h7wbk ,
(2s,5r,6r)-6-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
diclossacillina
bdbm50350476
AKOS016010072
dicloxacillin [inn]
(2s,5r,6r)-6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
dicloxacillin [mart.]
dicloxacillin [who-dd]
dicloxacillin [hsdb]
dicloxacillin [usan]
dicloxacillin [vandf]
dicloxacillin [mi]
EPITOPE ID:181860
SCHEMBL23955
3-(2,6-dichlorophenyl)-5-methyl-4-isooxazolylpenicillin
DTXSID1022924 ,
SBI-0051342.P003
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,6-[[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-,(2s,5r,6r)-
1-(4-chloro-benzyl)-piperidine-4-carboxylicacid
Q2313471
(2s,5r,6r)-6-(3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-6-[[3-(2,6-dichlorophenyl)-5-methyl1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
gtpl12261
EN300-708779
3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl penicillin
CS-0013566
HY-B1459A
dicloxacilline (inn-french)
j01cf01
dicloxacillin (mart.)
dicloxacillinum (inn-latin)
dicloxacilina (inn-spanish)
(2s,5r,6r)-6-(((3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
dtxcid202924
6beta-((3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl)carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
dicloxacillina

Research Excerpts

Overview

Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism. We recommend caution when prescribing it to users of drugs with a narrow therapeutic window.

ExcerptReferenceRelevance
"Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism, and we recommend caution when prescribing dicloxacillin to users of drugs with a narrow therapeutic window."( Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.
Brøsen, K; Damkier, P; Graff, M; Khojasteh, SC; Kroetz, DL; Nielsen, F; Pottegård, A; Rasmussen, LL; Stage, TB; Wong, S, 2018
)
3.37

Effects

Dicloxacillin has a significant antibacterial activity against MSSA, CNS, and other.

ExcerptReferenceRelevance
"Dicloxacillin has a significant antibacterial activity against MSSA, CNS, and other "( Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Fang, J; Ji, J; Shen, P; Xiao, T; Xiao, Y; Ying, C; Yu, W, 2017
)
2.14
"Dicloxacillin has a significant antibacterial activity against MSSA, CNS, and other "( Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Fang, J; Ji, J; Shen, P; Xiao, T; Xiao, Y; Ying, C; Yu, W, 2017
)
2.14
"Dicloxacillin has lower values of the standard Gibbs energies of adsorption than does cloxacillin, which gives this drug a more marked escaping tendency from the aqueous environment to the air-water monolayer."( Surface and bulk properties of two anionic amphiphilic penicillins in a selective solvent.
Antelo, LT; Barbosa, S; Mosquera, V; Taboada, P, 2006
)
1.06

Actions

ExcerptReferenceRelevance
"Dicloxacillin has lower values of the standard Gibbs energies of adsorption than does cloxacillin, which gives this drug a more marked escaping tendency from the aqueous environment to the air-water monolayer."( Surface and bulk properties of two anionic amphiphilic penicillins in a selective solvent.
Antelo, LT; Barbosa, S; Mosquera, V; Taboada, P, 2006
)
1.06

Treatment

ExcerptReferenceRelevance
"The dicloxacillin-treated patients had an increase in creatinine and beta 2-microglobulin in serum that was not seen in the cloxacillin group."( Renal function after hip arthroplasty and isoxazolylpenicillin prophylaxis.
Djerf, K; Ivarsson, I; Maller, R; Wahlström, O, 1992
)
0.76

Toxicity

ExcerptReferenceRelevance
" These cells were exposed to antibiotics for 24 hr and subsequently toxic effects on cells were evaluated by three different assays."( Cytotoxic effects of four antibiotics on endothelial cells.
Lanbeck, P; Paulsen, O, 1995
)
0.29
" No serious adverse events were reported."( Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2015
)
0.7
"Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the Cmax and AUC0-10 h values."( Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2015
)
2.15

Pharmacokinetics

Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the Cmax and AUC0-10 h values. The only striking pharmacokinetic differences observed were that the urinary recovery of active dicl Oxacillin is higher in young subjects and that the non-renal clearance was higher in elderly volunteers.

ExcerptReferenceRelevance
" The elimination rate was similar in all groups and the only striking pharmacokinetic differences observed were that the urinary recovery of active dicloxacillin was higher in young subjects and that the non-renal clearance was higher in elderly volunteers."( Single-dose pharmacokinetics of dicloxacillin in healthy subjects of young and old age.
Bucht, G; Hermansson, B; Holm, SE; Löfgren, S; Norrby, SR; Winblad, B, 1986
)
0.75
" Pharmacokinetic evaluation of the data suggests that the higher serum concentrations were primarily the result of changes in the extravascular distribution for dicloxacillin in the presence of sulfaethidole."( Influence of sulfaethidole on the human pharmacokinetics of dicloxacillin.
DeSante, KA; Dittert, LW; Doluisio, JT; Stavchansky, S,
)
0.57
" PKQuest, a new generic physiologically based pharmacokinetic software routine (PBPK), provides a novel approach to modeling capillary permeability in which the only adjustable parameter is the PS of muscle."( PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.
Levitt, DG, 2002
)
0.53
"All the results were obtained by applying PKQuest to previously published human pharmacokinetic data."( PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.
Levitt, DG, 2002
)
0.53
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Single-center, prospective, open-label, randomized, three-part crossover pharmacokinetic study."( Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X, 2008
)
0.58
" The objective of this study was to evaluate the safety and pharmacokinetic profile of dicloxacillin after single and multiple oral dose in healthy Chinese volunteers."( Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2015
)
0.93
" Plasma and urine pharmacokinetic samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method."( Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2015
)
0.7
"Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the Cmax and AUC0-10 h values."( Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses.
Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2015
)
2.15

Compound-Compound Interactions

The effect of rifampicin in combination with dicloxacillin or fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus in human neutrophil granulocytes was studied.

ExcerptReferenceRelevance
"The effect of rifampicin in combination with dicloxacillin or fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus in human neutrophil granulocytes in the presence of serum was studied."( Extracellular and intracellular killing in neutrophil granulocytes of Staphylococcus aureus with rifampicin in combination with dicloxacillin or fusidic acid.
Black, FT; Nielsen, SL, 1999
)
0.77
"To investigate the efficacy of conservative systemic treatment with dicloxacillin (DCX) in combination with TDZ (DCX+TDZ), compared to DCX alone, against early APVGI caused by methicillin-sensitive Staphylococcus aureus (MSSA) in a porcine model."( Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.
Andersen, TE; Behr-Rasmussen, C; Grønnemose, RB; Klein, K; Klitgaard, JK; Kolmos, HJ; Lindholt, JS; Stenger, M, 2017
)
0.95
" The in vitro results corroborated this drug-drug interaction and correlated to the clinical findings."( Dicloxacillin-warfarin drug-drug interaction-A register-based study and in vitro investigations in 3D spheroid primary human hepatocytes.
Dalgård Dunvald, AC; Ernst, MT; Hammer, HS; Järvinen, E; Pottegård, A; Pötz, O; Stage, TB, 2023
)
2.35

Bioavailability

We determined the apparent bioavailability of dicloxacillin in 26 children between the ages of 0. and 0.5 years. In healthy volunteers the bioavailability after oral administration of 2 gm dic lxacillin or 2 gM cloxacillus amounted to 48.

ExcerptReferenceRelevance
" In healthy volunteers the bioavailability after oral administration of 2 gm dicloxacillin or 2 gm cloxacillin amounted to 48."( Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects.
Mattie, H; Nauta, EH, 1976
)
1.93
" This assay has been employed in a study of the relative bioavailability of two commercial flucloxacillin sodium capsules in ten healthy volunteers."( Optimization of high-performance liquid chromatographic analysis for isoxazolyl penicillins using factorial design.
Hung, CT; Lam, FC; Lim, JK; Zoest, AR, 1988
)
0.27
"The bioavailability of commercial liquid preparations of di- and flucloxacillin was compared in infants and children."( Plasma concentration following oral administration of di- and flucloxacillin in infants and children.
Bergdahl, S; Eriksson, M; Finkel, Y, 1987
)
0.27
"Flucloxacillin, a new isoxazole penicillin, is active against penicillinase-producing strains of Staphylococcus aureus and is well absorbed in man after oral and intramuscular administration."( Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.
Croydon, EA; Rolinson, GN; Sutherland, R, 1970
)
0.47
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The antibiotics should be well absorbed after oral administration, have a high intrinsic activity against the offending pathogen, and be given at intervals leading to inhibitory blood concentrations throughout most of the day."( [Long-term antibiotic suppressive therapy for an infected thoracic aorta graft].
Berdal, JE; Steinbakk, M, 2003
)
0.32
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Two multivariate chemometric models, namely, partial least-squares regression (PLSR) and linear support vector regression (SVR), are presented for the analysis of amoxicillin trihydrate and dicloxacillin sodium in the presence of their common impurity (6-aminopenicillanic acid) in raw materials and in pharmaceutical dosage form. The results highlight the advantages and limitations of each model.

ExcerptRelevanceReference
"A neonate treated initially with oxacillin intravenously for two weeks and who was receiving phenobarbital for a seizure disorder subsequently failed to achieve therapeutic levels of orally administered dicloxacillin, even when the dosage was as high as 175 mg/kg/day."( Subtherapeutic dicloxacillin levels in a neonate: possible mechanisms.
Hegyi, T; Schwartz, GJ; Spitzer, A, 1976
)
0.8
" The drugs were given in routine oral dosage for eight days to two patient groups each consisting of 50 patients."( A comparison of dicloxacillin and ampicillin in the antibiotic prophylaxis of total hip replacement.
Antila, P; Laurent, LE; Visuri, T, 1976
)
0.6
" The drugs were given in routine oral dosage for eight days to two patient groups each consisting of 50 patients."( A comparison of dicloxacillin and ampicillin in the antibiotic prophylaxis of total hip replacement.
Antila, P; Laurent, LE; Visuri, T, 1976
)
0.6
" The method is precise, accurate and applicable to the analysis of commercial dosage form."( HPLC determination of K-hetacillin and Na-dicloxacillin in oily suspension.
Caccialanza, G; Gandini, C; Kitsos, M; Massolini, G,
)
0.4
" Clinical or animal studies are needed to establish whether the higher titers observed with patient serum containing highly protein-bound drugs diluted in low protein-content media would foster inadequate dosage regiments."( Laboratory evaluation of the serum dilution test in serious staphylococcal infection.
Bartlett, RC; Marcon, MJ, 1983
)
0.27
" For dicloxacillin, however, the same dosage adjustment is required irrespective of whether administration is single or combined."( Effects of mezlocillin on the pharmacokinetics of oxacillin and dicloxacillin.
Kampf, D, 1983
)
1.02
"Pharmacokinetics of dicloxacillin and ampicillin dosed individually and in combination were investigated by means of moment analyses of urinary excretions of intact forms and metabolic products of parent penicillins."( Comparative pharmacokinetics of dicloxacillin and ampicillin between individual and combined doses.
Murai, Y; Nakagawa, T; Uno, T; Yamaoka, K, 1984
)
0.87
" Twice-daily dosing with oral antibiotics is obviously convenient and may enhance compliance."( Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin.
Dillon, HC, 1983
)
0.5
"Reduction in the dosage of dicloxacillin from 500 mg to 250 mg 3 times a day would mean lowering of costs and less side-effects in orthopaedic infections."( Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid.
Hansen, BA; Jensen, P; Krogsgaard, MR; Slotsbjerg, T, 1994
)
0.85
" It may be important to take account of the PAE when designing dosing regimens."( Postantibiotic effect of aminoglycosides on staphylococci.
Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1993
)
0.29
"Careful monitoring of international normalized ratios and titration of the warfarin dosage is recommended on initiation and for 3 weeks after discontinuation of dicloxacillin in patients receiving warfarin."( Potential interaction between warfarin and dicloxacillin.
Gidal, BE; Mailloux, AT; Sorkness, CA, 1996
)
0.75
"4 and an increased warfarin dosage was required for three weeks following discontinuation of dicloxacillin treatment in order to maintain therapeutic INRs."( Prosthetic heart valve thrombosis during dicloxacillin therapy.
Arnesen, H; Halvorsen, S; Husebye, T, 1999
)
0.79
" Eight cows and eight sheep, four of each group in low and four in high milk production, were dosed with 200 mg dicloxacillin/quarter in cows and 100 mg dicloxacillin/quarter in sheep, three times at 12 h intervals."( Milk depletion of dicloxacillin residues in cows and sheep following intramammary administration.
Ermini, L; Roncada, P; Stracciari, GL; Strocchia, A; Tomasi, L, 2000
)
0.85
" The method is applicable for the assay of the four drugs under investigation in different dosage forms and the results are in good agreement with those obtained by the official method."( Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate.
Mohamed, GG, 2001
)
0.31
"Focus eradication and the dosing of penicillinase-stable penicillin are important to the outcome of S aureus bacteremia."( Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases.
Espersen, F; Frimodt-Møller, N; Jensen, AG; Scheibel, J; Skinhøj, P; Wachmann, CH, 2002
)
0.31
" Eighteen healthy volunteers received two 1-g doses of dicloxacillin, one on the 1st study day and the other on the 11th day of rifampin dosing (600 mg daily)."( Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics.
Benet, LZ; Huang, Y; Putnam, WS; Woo, JM, 2005
)
0.81
"Impurity profiling of dicloxacillin sodium bulk drug and pharmaceutical dosage forms subjected to stability studies is evaluated."( Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
Bharati, CH; Narayan, GK; Parikh, K; Raj, TJ; Rao, KR; Rao, PS, 2007
)
0.89
" Multiple dosing of DCX in vivo revealed increased extra- and intracellular efficacies (2."( Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
Baudoux, P; Frimodt-Møller, N; Jensen, KS; Sandberg, A; Tulkens, PM; Van Bambeke, F, 2010
)
0.63
"A simple, precise, accurate, and sensitive RP-HPLC method for simultaneous determination of cefixime trihydrate and dicloxacillin sodium in combined tablet dosage form was developed and validated."( Simultaneous determination of cefixime trihydrate and dicloxacillin sodium in pharmaceutical dosage form by reversed-phase high-performance liquid chromatography.
Dhoka, MV; Dumbre, SC; Sandage, SJ,
)
0.59
" This stresses the importance of an optimal dosing of the antibiotic when SCVs are present."( Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.
Frimodt-Møller, N; Hughes, D; Lemaire, S; Sandberg, A; Tulkens, PM; Van Bambeke, F; von Eiff, C, 2011
)
0.64
"Two multivariate chemometric models, namely, partial least-squares regression (PLSR) and linear support vector regression (SVR), are presented for the analysis of amoxicillin trihydrate and dicloxacillin sodium in the presence of their common impurity (6-aminopenicillanic acid) in raw materials and in pharmaceutical dosage form via handling UV spectral data and making a modest comparison between the two models, highlighting the advantages and limitations of each."( Partial Least-Squares and Linear Support Vector Regression Chemometric Methods for Simultaneous Determination of Amoxicillin Trihydrate and Dicloxacillin Sodium in the Presence of Their Common Impurity.
Abdelaleem, EA; Hussein, EA; Naguib, IA; Zaazaa, HE, 2016
)
0.83
" The objective of this study was to obtain optimal dosing regimen of oral administration of dicloxacillin by analyzing the pharmacokinetic (PK) index in healthy volunteers and in vitro antibacterial activity by using Monte Carlo simulation."( Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Fang, J; Ji, J; Shen, P; Xiao, T; Xiao, Y; Ying, C; Yu, W, 2017
)
0.92
" Based on the MICs and the PK parameters of different dosage regimens, Monte Carlo simulation was performed to simulate the PK/pharmacodynamic indices of 250 mg once-daily (qd), 500 mg qd, 1,000 mg qd, 2,000 mg qd, 250 mg every 6 hours (q6h), and 500 mg q6h, respectively."( Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Fang, J; Ji, J; Shen, P; Xiao, T; Xiao, Y; Ying, C; Yu, W, 2017
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)111.10000.40002.75008.6000AID1209456
Solute carrier family 22 member 8Mus musculus (house mouse)IC50 (µMol)16.60003.02003.02003.0200AID1209730
Bile salt export pumpHomo sapiens (human)IC50 (µMol)45.27500.11007.190310.0000AID1209455; AID1443980; AID1449628; AID1473738
Solute carrier family 15 member 1Homo sapiens (human)Ki7,200.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki418.43450.79434.22108.0000AID612540
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki420.00003.00006.47788.5000AID681114
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (230)

Assay IDTitleYearJournalArticle
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516067Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at 100 times MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID518759Bactericidal activity against Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as log reduction in bacterial count at 10 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID516075Antimicrobial activity against Staphylococcus aureus ATCC 25923 by broth macrodilution method at pH 7.42010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID523273Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID516089Cmax in NMRI mouse at 1200 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516104Ratio of fAUC (24 hrs) in NMRI mouse at 120 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516079Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log change in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517997Bacteriostatic activity against Staphylococcus aureus E19977 infected in human THP-1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID516087Cmax in NMRI mouse at 30 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516136fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 80 mg/kg administered every 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516064Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in bacterial count at 100 times MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID516078Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells at MIC after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516088Cmax in NMRI mouse at 60 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID558275Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 10 to 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516095Ratio of fAUC (24 hrs) in NMRI mouse at 76 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516105Ratio of fAUC (24 hrs) in NMRI mouse at 400 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558241Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 20 mg/liter upto 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516109Ratio of fCmax in NMRI mouse at 76 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID517989fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 120 mg/kg administered every 6 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517987fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 240 mg/kg administered every 6 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558245Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 20 mg/liter after 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516120Ratio of fCmax in NMRI mouse at 300 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558249Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID523272Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa7 assessed as minimal drug concentration2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID516065Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in bacterial count at MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID523269Binding affinity to Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID518762Bacteriostatic activity against Staphylococcus aureus E19977 infected in human THP-1 cells at 10 times MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID516137fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 120 mg/kg administered every 3 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516118Ratio of fCmax in NMRI mouse at 120 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516097Ratio of fAUC (24 hrs) in NMRI mouse at 80 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516060Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in bacterial count at 10 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516069Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID558242Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 9 mg/liter after 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516125Protein binding in NMRI mouse at 180 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516124Protein binding in NMRI mouse at 270 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516117Ratio of fCmax in NMRI mouse at 200 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID518000Antimicrobial activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516100Ratio of fAUC (24 hrs) in NMRI mouse at 200 mg/kg administered every 4 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558024Half life in human at 1000 mg, po2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID516121Ratio of fCmax in NMRI mouse at 340 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516070Bacteriostatic activity against Staphylococcus aureus ATCC 25923 at MIC between 5 to 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516108Ratio of fAUC (24 hrs) in NMRI mouse at 120 mg/kg administered every 24 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516091Half-life in NMRI mouse at 30 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID518758Bactericidal activity against Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as log reduction in bacterial count at 100 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID516058Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells at MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516063Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in bacterial count at 10 times MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516122Ratio of fCmax in NMRI mouse at 120 mg/kg administered every 24 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558247Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID516135fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 30 mg/kg administered every 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558261Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 3 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516138fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 160 mg/kg administered every 3 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516076Bactericidal activity against Staphylococcus aureus E19977 infected in human THP1 cells assessed as log reduction in bacterial count at 100 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID518001Antimicrobial activity against Staphylococcus aureus E19977 infected in human THP-1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID523266Activity at Escherichia coli isolate 7181 beta-lactamase OXA-72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID517986fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 80 mg/kg administered every 8 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID554575Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 200 mg/kg, sc administered as single dose 2 hrs after infection measured between 4 to 19 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID517992fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 340 mg/kg administered every 12 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID516093Half-life in NMRI mouse at 120 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516082Bactericidal activity against Staphylococcus aureus E19977 infected in human THP-1 cells assessed as log change in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID518757Bactericidal activity against Staphylococcus aureus E19977 infected in human THP1 cells assessed as log reduction in bacterial count at 10 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516080Bactericidal activity against Staphylococcus aureus E19977 assessed as log change in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1474107AUC in human at 125 to 500 mg, po QID after 6 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516111Ratio of fCmax in NMRI mouse at 80 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516090Cmax in NMRI mouse at 300 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558264Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 3 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID523274Activity at Escherichia coli isolate 7181 beta-lactamase OXA-7 measured per mg of protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID558239Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 2 mg/liter upto 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID517991fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 300 mg/kg administered every 12 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516113Ratio of fCmax in NMRI mouse at 160 mg/kg administered every 3 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID518763Bacteriostatic activity against Staphylococcus aureus E19977 infected in human THP-1 cells at MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517999Antimicrobial activity against Staphylococcus aureus E19977 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID516129Protein binding in NMRI mouse at 10 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516127Protein binding in NMRI mouse at 60 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558256Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 1 hr after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID516071Cytotoxicity against human THP1 cells at 500 mg/L after 24 hrs by trypan blue exclusion method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID558246Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 0.5 mg/liter after 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID558279Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection evry 8 hrs as three-dose regimen measured after 12009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516101Ratio of fAUC (24 hrs) in NMRI mouse at 80 mg/kg administered every 8 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516068Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at 10 times MIC after 5 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517990fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 400 mg/kg administered every 12 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517994Bacteriostatic activity against Staphylococcus aureus ATCC 25923 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID516103Ratio of fAUC (24 hrs) in NMRI mouse at 200 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID516083AUC (24 hrs) in NMRI mouse at 30 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID554576Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 200 mg/kg, sc administered as single dose 2 hrs after infection measured between 4 to 19 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516098Ratio of fAUC (24 hrs) in NMRI mouse at 120 mg/kg administered every 3 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1209732Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method in presence of probenecid2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID558263Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523268Activity at Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID516073Antimicrobial activity against Staphylococcus aureus E19977 by broth macrodilution method at pH 7.42010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID516132Protein binding in NMRI mouse infected with Staphylococcus aureus E19977 at 30 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558274Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 10 to 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID558236Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 2 mg/liter after 12 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516130Protein binding in NMRI mouse infected with Staphylococcus aureus E19977 at 270 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID516128Protein binding in NMRI mouse at 30 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID554578Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 2 hrs after infection measured within 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516114Ratio of fCmax in NMRI mouse at 200 mg/kg administered every 4 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558244Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 1.5 mg/liter after 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID516074Antimicrobial activity against Staphylococcus aureus ATCC 25923 by broth macrodilution method at pH 5.42010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516086AUC (24 hrs) in NMRI mouse at 300 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516115Ratio of fCmax in NMRI mouse at 80 mg/kg administered every 8 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID516084AUC (24 hrs) in NMRI mouse at 60 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID516059Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in bacterial count at 100 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558276Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 10 to 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID523270Permeability across Escherichia coli HN1157/pHSG576oxa7 assessed as permeability coefficient in presence of proton uncoupler carbonyl cyanide meta-chlorophenylhydrazone2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID516094Half-life in NMRI mouse at 300 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516107Ratio of fAUC (24 hrs) in NMRI mouse at 340 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID558258Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 3 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID558277Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection evry 8 hrs as three-dose regimen measured after 19 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516092Half-life in NMRI mouse at 60 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID518761Bacteriostatic activity against Staphylococcus aureus E19977 infected in human THP-1 cells at 100 times MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516112Ratio of fCmax in NMRI mouse at 120 mg/kg administered every 3 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1474108Drug concentration at steady state in human at 125 to 500 mg, po QID after 6 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516081Bactericidal activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells assessed as log change in bacterial count after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID516077Antimicrobial activity against Staphylococcus aureus E19977 infected in human THP1 cells assessed as log reduction in bacterial count at MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516099Ratio of fAUC (24 hrs) in NMRI mouse at 160 mg/kg administered every 3 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID558260Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516057Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells at 10 times MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID558240Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 1.5 mg/liter upto 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID523271Lipophilicity, log P of the compound2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID558248Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516133Protein binding in NMRI mouse infected with Staphylococcus aureus E19977 at 10 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558259Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 1 hr after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID558015Antibacterial activity against Staphylococcus aureus E19977 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID517993fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 120 mg/kg administered every 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID518760Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells at compound MIC after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID516116Ratio of fCmax in NMRI mouse at 240 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558020Protein binding in human serum at 1000 mg, po2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516085AUC (24 hrs) in NMRI mouse at 1200 mg/kg, sc2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1209731Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID516061Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at 100 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516123Protein binding in NMRI mouse at 400 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID558243Bactericidal activity against Staphylococcus aureus E19977 assessed as log reduction in cfu at 2 mg/liter after 24 hrs by time-kill study2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID516072Antimicrobial activity against Staphylococcus aureus E19977 by broth macrodilution method at pH 5.42010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516110Ratio of fCmax in NMRI mouse at 30 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID517996Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558278Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in intracellular bacterial cfu in peritoneum at 200 mg/kg, sc administered 2 hrs after infection evry 8 hrs as three-dose regimen measured after 12009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID517988fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 200 mg/kg administered every 6 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516332fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 200 mg/kg administered every 4 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516102Ratio of fAUC (24 hrs) in NMRI mouse at 240 mg/kg administered every 6 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516126Protein binding in NMRI mouse at 90 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516062Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as log reduction in bacterial count at 10 times MIC after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID558257Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 2 hrs after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID558262Antibacterial activity against Staphylococcus aureus E19977 infected in NMRI mouse assessed as log reduction in extracellular bacterial cfu in peritoneum at 60 mg/kg, sc administered as single dose 1 hr after infection measured after 4 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID516056Bacteriostatic activity against Staphylococcus aureus ATCC 25923 infected in human THP-1 cells at 100 times MIC after 5 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID558016Cmax in human at 1000 mg, po2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.
AID517995Bacteriostatic activity against Staphylococcus aureus E19977 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID516096Ratio of fAUC (24 hrs) in NMRI mouse at 30 mg/kg administered every 2 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1209730Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1474109Ratio of drug concentration at steady state in human at 125 to 500 mg, po QID after 6 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516119Ratio of fCmax in NMRI mouse at 400 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516134fT>MIC in Staphylococcus aureus E19977 infected NMRI mouse at 76 mg/kg administered every 2 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID516106Ratio of fAUC (24 hrs) in NMRI mouse at 300 mg/kg administered every 12 hrs to MIC for Staphylococcus aureus E199772010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID516066Bacteriostatic activity against Staphylococcus aureus E19977 at MIC between 5 to 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID517998Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID516131Protein binding in NMRI mouse infected with Staphylococcus aureus E19977 at 90 mg/l by ultrafiltration2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (590)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990407 (68.98)18.7374
1990's61 (10.34)18.2507
2000's60 (10.17)29.6817
2010's53 (8.98)24.3611
2020's9 (1.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.59 (24.57)
Research Supply Index6.53 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index164.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (90.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (8.76%)5.53%
Reviews25 (3.98%)6.00%
Case Studies80 (12.74%)4.05%
Observational0 (0.00%)0.25%
Other468 (74.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia [NCT03108690]Phase 40 participants (Actual)Interventional2017-10-01Withdrawn(stopped due to Logistics)
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) [NCT05156437]Phase 420 participants (Anticipated)Interventional2022-03-16Enrolling by invitation
The Pathogenic Role Of Staphylococcus Aureus And The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis [NCT05578482]Phase 445 participants (Anticipated)Interventional2022-10-24Recruiting
The Effect of Dicloxacillin on Oral Absorption of Drugs [NCT05073627]Phase 112 participants (Actual)Interventional2022-02-07Completed
Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections [NCT00037050]Phase 3739 participants (Actual)Interventional2002-04-30Completed
Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolizing Enzymes. [NCT02983890]Phase 112 participants (Actual)Interventional2016-10-06Completed
Oral-only Antibiotics for Bone and Joint Infections in Children - A Nationwide Randomized Controlled Trial [NCT04563325]Phase 4180 participants (Actual)Interventional2020-09-15Active, not recruiting
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679]Phase 4360 participants (Anticipated)Interventional2022-06-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]